Pall (BUE:PLL) Total Liabilities : ARS18,751.66 Mil (As of Apr. 2015)

View and export this data going back to . Start your Free Trial

What is Pall Total Liabilities?

Pall's Total Liabilities for the quarter that ended in Apr. 2015 was ARS18,751.66 Mil.

Pall's quarterly Total Liabilities declined from Oct. 2014 (ARS18,490.10 Mil) to Jan. 2015 (ARS18,296.53 Mil) but then increased from Jan. 2015 (ARS18,296.53 Mil) to Apr. 2015 (ARS18,751.66 Mil).

Pall's annual Total Liabilities increased from Jul. 2012 (ARS8,426.58 Mil) to Jul. 2013 (ARS9,018.88 Mil) and increased from Jul. 2013 (ARS9,018.88 Mil) to Jul. 2014 (ARS15,970.39 Mil).

Pall Total Liabilities Historical Data

The historical data trend for Pall's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pall Total Liabilities Chart

Pall Annual Data

Trend

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Jul14

Total Liabilities

Get a 7-Day Free Trial

7,158.44

7,223.06

8,426.58

9,018.88

15,970.39

Pall Quarterly Data
	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15
Total Liabilities	Get a 7-Day Free Trial															14,604.41	15,970.39	18,490.10	18,296.53	18,751.66

Pall Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pall's Total Liabilities for the fiscal year that ended in Jul. 2014 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8956.791	+	(3066.74	+	1708.419
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	556.512	+	1681.931)
	=	15,970.39

Total Liabilities	=	Total Assets (A: Jul. 2014 )	-	Total Equity (A: Jul. 2014 )
	=	31436.506	-	15466.113
	=	15,970.39

Pall's Total Liabilities for the quarter that ended in Apr. 2015 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11509.761	+	(3325.656	+	997.264
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2918.978	+	0)
	=	18,751.66

Total Liabilities	=	Total Assets (Q: Apr. 2015 )	-	Total Equity (Q: Apr. 2015 )
	=	33306.899	-	14555.24
	=	18,751.66

Pall Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pall's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pall (BUE:PLL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Pall Corporation (BUE:PLL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.pall.com

Pall Corporation is a New York corporation incorporated on July 31, 1946. The Company supplies filtration, separation and purification technologies. Its products are used to remove solid, liquid and gaseous contaminants from a variety of liquids and gases. Its serves its customers through two businesses: Life Sciences and Industrial. The Life Sciences business group is engaged in developing, manufacturing and selling products to customers in the BioPharmaceutical, Food & Beverage and Medical markets. The Industrial business group is engaged in developing, manufacturing and selling products to customers in the Process Technologies, Aerospace and Microelectronics markets. The Life Sciences technologies facilitate the process of drug discovery, development, regulatory validation and production, and are used in research laboratories, and the pharmaceutical and biotechnology industries. It also supplies products and technologies for food and beverage industries and in hospitals at the point of patient care. The Industrial segment provides enabling and process-enhancing technologies throughout the industrial marketplace. These include the Process Technologies, Aerospace and Microelectronics markets. It has the capability to provide customers with integrated solutions using its proprietary consumable filtration products for their process fluids. The Company's competition varies by product and application. Its competitors in the BioPharmaceuticals market include Merck Millipore (a division of Merck KGaA), The Sartorius Group and GE Healthcare (a unit of General Electric Company ("GE")). Its competitors in the Food & Beverage market include 3M Purification, Pentair, Inc., Filtrox Group, The Sartorius Group, Eaton Corporation and Parker Domnick Hunter (a division of Parker Hannifin). Its competitors in the Medical market include Merck Millipore, GE Healthcare, Teleflex Incorporated, Covidien plc and Intersurgical, Ltd. Its competitors in the Process Technologies market include CLARCOR Inc., Donaldson Company, Inc., Parker Hannifin Corporation, HYDAC International GmbH, GE Infrastructure (a unit of GE), Pentair, Inc., 3M Purification, U.S. Filter (a unit of Siemens AG) and ESCO Technologies Inc. Its competitors in the Aerospace market include Donaldson Company, Inc. and ESCO Technologies Inc. Its competitors in the Microelectronics market include Entegris, Inc., Parker Hannifin Corporation and Mott Corporation. The Company is subject to competition in all of the global markets in which it operates.